EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Real‐world effectiveness of monoclonal antibody inhibitors of PCSK 9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study

Rebecca Siemens, Mark Pryjma, Susan Buchkowsky, Arden R Barry iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4609 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Rebecca Siemens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Surrey Memorial Hospital, Fraser Health (Lower Mainland Pharmacy Services), Surrey, British Columbia, Canada. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hyperlipoproteinemia Type II, Cholesterol, LDL, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heterozygous familial hypercholesterolemia (HeFH) is a genetic condition that is associated with a high risk of atherosclerotic cardiovascular disease (ASCVD) due to elevated lipid levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody inhibitors have been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) substantially. This study aimed to assess the real‐world effectiveness of PCSK9 inhibitor therapy among patients with HeFH.

Methods

Retrospective cohort study of patients with probable or definite HeFH on a PCSK9 inhibitor at a specialized lipid clinic between 2015 and 2022. The primary objective was the proportion of patients who attained a ≥50% reduction in LDL‐C after 12 months of treatment.

Results

In total, 141 patients were screened and 95 were included. Mean age was 63 years, 51% were female, and mean baseline LDL‐C level was 4.0 mmol/L (155 mg/dL). A majority of patients (60%) had statin intolerance, and 73% were on ezetimibe. The most common PCSK9 inhibitor was evolocumab (94%). Overall, 74% of patients achieved a ≥50% reduction in LDL‐C after 12 months of therapy. Mean LDL‐C concentration decreased to 1.7 mmol/L (66 mg/dL) (approximately 59% reduction from baseline) after 12 months of follow‐up but increased to 1.9 mmol/L (73 mg/dL) after ≥24 months of follow‐up. Similar trends were observed in non‐high‐density lipoprotein cholesterol and apolipoprotein B. Lipoprotein(a) was significantly reduced by 45% over 12 months. Twelve percent of patients permanently discontinued therapy. Barriers to PCSK9i use were mostly related to cost.

Conclusions

In a real‐world cohort of HeFH patients, most of which were intolerant to statins, a high majority were able to achieve a ≥50% reduction in LDL‐C after 12 months of PCSK9 inhibitor therapy (mean reduction of approximately 59%), which is similar to clinical trial data of patients with ASCVD. A significant reduction in non‐high‐density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) were also observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsHyperlipoproteinemia Type IICholesterol, LDLAnticholesteremic AgentsAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesMaleMiddle AgedFemaleAgedCohort StudiesAntibodies, MonoclonalTreatment OutcomeHeterozygoteProprotein Convertase 9

Stichwörter der Autor:innen

PCSK9 inhibitorsdyslipidemiashyperlipoproteinemia type II

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanCholesterol, LDLAnticholesteremic AgentsAntibodies, Monoclonal, HumanizedevolocumabAntibodies, MonoclonalProprotein Convertase 9

Autor:innen und Institutionen

  • Surrey Memorial Hospital, Fraser Health (Lower Mainland Pharmacy Services), Surrey, British Columbia, Canada.
  • Jim Pattison Outpatient Care and Surgery Centre, Fraser Health (Lower Mainland Pharmacy Services), Surrey, British Columbia, Canada.
  • Richmond Hospital, Vancouver Coastal Health (Lower Mainland Pharmacy Services), Richmond, British Columbia, Canada.
  • Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Arden R Barry

Zitieren

APA

Siemens, R., Pryjma, M., Buchkowsky, S., & Barry, A. R. (2024). Real‐world effectiveness of monoclonal antibody inhibitors of PCSK 9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4609

Vancouver

Siemens R, Pryjma M, Buchkowsky S, Barry AR. Real‐world effectiveness of monoclonal antibody inhibitors of PCSK 9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4609

BibTeX
@article{Siemens2024,
  author = {Siemens, Rebecca and Pryjma, Mark and Buchkowsky, Susan and Barry, Arden R},
  title = {Real‐world effectiveness of monoclonal antibody inhibitors of PCSK 9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4609}
}
Kostenlos starten →